Introductory paragraph
The SARS-CoV-2 pandemic likely began by viral spillover from animals to humans1-3; today multiple animal species are known to be susceptible to infection4-8. White-tailed deer, Odocoileus virginianus are infected in North America at substantial levels9-11, and genomic data suggests that a variant in deer may have spilled back to humans12,13. Here we characterize SARS-CoV-2 in deer from Pennsylvania (PA) sampled during fall and winter 2021. Of 123 nasal swab samples analyzed by RT-qPCR, 20 (16.3%) were positive for SARS-CoV-2. Seven whole-genome sequences were obtained, together with six more partial spike sequences. These annotated as alpha and delta variants, the first reported observations of these lineages in deer, documenting multiple new jumps from humans to deer. The alpha lineage persisted in deer after its displacement by delta in humans, and deer-derived alpha variants diverged significantly from those in humans, consistent with a distinctive evolutionary trajectory in deer.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by the Penn University Research Foundation. SG is supported by the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation. Funding was provided by a contract award from the Centers for Disease Control and Prevention (CDC BAA 200-2021-10986 and 75D30121C11102/000HCVL1-2021-55232), philanthropic donations to the Penn Center for Research on Coronaviruses and Other Emerging Pathogens, and in part by NIH grant R61/33-HL137063 and AI140442 -supplement for SARS-CoV-2. BJK is supported by NIH K23 AI 121485. Additional assistance was provided by the Penn Center for AIDS Research (P30-AI045008). HZs stipend to conduct this work was provided by a private donation by Tracy Holmes. This project has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00015.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human sequences newly determined here were collected as follows. For most samples, the University of Pennsylvania Institutional Review Board (IRB) reviewed the research protocol and deemed the limited data elements extracted to be exempt from human subject research per 45 CFR 46.104, category 4 (IRB #848605). For hospitalized subjects, following informed consent (IRB protocol #823392), patients were sampled by collection of saliva, oropharyngeal and/or nasopharyngeal swabs, or endotracheal aspirates if intubated, as previously described. Further samples were collected from asymptomatic subjects detected in a screening program at the Perelman School of Medicine at the University of Pennsylvania and symptomatic subjects tested throughout the PennMedicine clinical network under IRB protocols #843565 and #848608.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
